0950 Effects of Sodium Oxybate (SXB) on Body Mass Index (BMI) in Pediatric Patients With Narcolepsy
| العنوان: | 0950 Effects of Sodium Oxybate (SXB) on Body Mass Index (BMI) in Pediatric Patients With Narcolepsy |
|---|---|
| المؤلفون: | Michel Lecendreux, D. Menno, Yves Dauvilliers, G. Plazzi, Kiran Maski, Carol L. Rosen, Gert Jan Lammers, Y.G. Wang, S Kansagra, Emmanuel Mignot |
| المصدر: | Sleep. 43:A361-A361 |
| بيانات النشر: | Oxford University Press (OUP), 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Pediatrics, medicine.medical_specialty, Cataplexy, business.industry, Sodium Oxybate, Overweight, medicine.disease, Comorbidity, Weight loss, Physiology (medical), Medicine, Neurology (clinical), medicine.symptom, Underweight, business, Body mass index, Narcolepsy |
| الوصف: | Introduction Obesity is a common comorbidity of pediatric narcolepsy. SXB is a standard of care for cataplexy and excessive daytime sleepiness in narcolepsy. BMI decreases have been observed with SXB treatment. We examined BMI changes by BMI percentile category at study entry in pediatric participants. Methods Participants were aged 7-17 years with narcolepsy with cataplexy. SXB-naive participants were titrated to an optimal SXB dose, then entered a 2-week stable-dose period; participants taking SXB at study entry entered a 3-week stable-dose period. After a 2-week, placebo-controlled, double-blind, randomized-withdrawal period, all participants entered an open-label safety period (total study duration: ≤1 year). Weight categories were defined using BMI percentiles at study entry based on growth charts from the Centers for Disease Control. BMI percentile was categorized as: underweight ( Results Among SXB-naive participants, median (Q1, Q3) BMI percentile decreased with SXB treatment in participants who were categorized as normal-weight and overweight/obese at baseline (normal-weight, n=16: 76.5 [57.8, 82.4] at baseline, 35.0 [20.5, 62.6] at week 52; overweight/obese, n=35: 97.6 [93.6, 99.1] at baseline, 86.7 [72.5, 97.9] at week 52). Of participants who were normal-weight at baseline, 15/16 remained normal-weight at week 52. Of participants who were overweight at baseline, 9/10 were normal-weight at week 52. Of participants who were obese at baseline, 7/25 were normal-weight, 3/25 were overweight, and 15/25 remained obese at week 52. Among participants taking SXB at study entry, BMI percentile decreased, but to a lesser degree. Decreased weight or weight loss was reported as an adverse event in 13 participants (11 SXB-naive; 1 participant withdrew). Four participants became underweight during the study but returned to normal-weight by study end. Conclusion Decreases in BMI percentile and category were observed with SXB treatment in pediatric participants with narcolepsy. Support Jazz Pharmaceuticals |
| تدمد: | 1550-9109 0161-8105 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::2243f7f72402721a14887373179813a4 https://doi.org/10.1093/sleep/zsaa056.946 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi...........2243f7f72402721a14887373179813a4 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15509109 01618105 |
|---|